Matinas BioPharma Holdings (MTNB) Current Leases (2014 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Current Leases of $718000.0 for Q1 2026, up 11866.67% year-over-year from N/an in Q1 2025, and up 3.46% quarter-over-quarter from $694000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Current Leases (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Current Leases for 13 consecutive years, with $718000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 11866.67% year-over-year to $718000.0; the TTM figure through Mar 2026 stood at $718000.0 (up 11866.67% YoY), while the FY2025 annual figure was $694000.0, down 8.8% from the prior year.
- Current Leases rose to $718000.0 in Q1 2026 per MTNB's latest filing, from $694000.0 in the prior quarter.
- Across five years, Current Leases topped out at $846000.0 in Q3 2025 and bottomed at $4000.0 in Q1 2023.
- Historically, Current Leases has averaged $378886.5 across 5 years, with a median of $558702.0 in 2022.
- Annual changes were most pronounced in 2023 — Current Leases tumbled 99.28% — and 2025, when it soared 16820.0%.
- Matinas BioPharma Holdings' Current Leases stood at $7000.0 in 2022, then jumped by 9271.43% to $656000.0 in 2023, then advanced by 16.01% to $761000.0 in 2024, then fell by 8.8% to $694000.0 in 2025, then gained by 3.46% to $718000.0 in 2026.
- Business Quant data shows MTNB's Current Leases at $718000.0 in Q1 2026, $694000.0 in Q4 2025, and $846000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Mar 31, 2026 | 718,000.00 |
| Dec 31, 2025 | 694,000.00 |
| Sep 30, 2025 | 846,000.00 |
| Jun 30, 2025 | 817,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Dec 31, 2024 | 761,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 707,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 656,000.00 |
| Sep 30, 2023 | 632,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | 7,000.00 |
| Sep 30, 2022 | 7,860.00 |
| Jun 30, 2022 | 11,508.00 |
| Mar 31, 2022 | 558,702.00 |
| Dec 31, 2021 | 21,000.00 |
| Sep 30, 2021 | 24,309.00 |